PharmaCyte Biotech’s (OTCMKTS:PMCB) encapsulation technology could soon transform the treatment and management of difficult-to-treat diseases.  The company is nearing the second phase of clinical evaluation in locally advanced pancreatic...

Clinical stage biotechnology firm Pharmacyte Biotech Inc (OTCMKTS:PMCB) announced on Thursday that David A. Judd is the latest executive to join its Medical and Scientific Advisory board. The company believes that Judd is a great addition...

Mr. David Judd, a consultant cellular biologist, and Chief Executive Officer of Pharmacyte Biotech Inc (OTCMKTS:PMCB), Kenneth L. Waggoner will visit the GMP production facility of Austrianova in Bangkok, Thailand. They will oversee the production...

Pharmacyte Biotech Inc (OTCMKTS:PMCB) currently working on its Investigational New Drug application and has sought the expertise of cGMP Validation to ensure that they submit a flawless masterpiece to the U.S Food and Drug Administration (FDA)...

Pharmacyte Biotech Inc (OTCMKTS:PMCB) announced that Eurofins Lancaster Laboratories, a major Contract Manufacturing Organization that company selected to set its Master Cell Bank, has successfully concluded its independent growth assessment...

Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that its senior management will attend the annual meeting of the ASCO. The theme of this meeting is focused on bringing a difference in cancer care. Kenneth L. Waggoner, the CEO, reported that this...